Back to today’s briefing

Story perspectives

Vutrisiran Shows Promising Heart Benefits in ATTR-CM Trial

8/6/2025

50 12

Summary

Story summary

In the groundbreaking HELIOS-B trial, vutrisiran demonstrated remarkable improvements in cardiac structure and function for patients battling ATTR-CM over 30 months. It notably enhanced diastolic function and slowed the deterioration of left ventricular systolic function and wall thickness, positioning vutrisiran as a promising disease-modifying therapy that could lower cardiovascular risks and save lives.

1 of 1

Story summary

In the groundbreaking HELIOS-B trial, vutrisiran demonstrated remarkable improvements in cardiac structure and function for patients battling ATTR-CM over 30 months. It notably enhanced diastolic function and slowed the deterioration of left ventricular systolic function and wall thickness, positioning vutrisiran as a promising disease-modifying therapy that could lower cardiovascular risks and save lives.